Biotech

All Articles

Lilly messages extra beneficial records on its own weekly insulin possibility

.On the heels of an FDA rejection for its own chief competing Novo Nordisk, Eli Lilly is pulling ahe...

IN 8bio stops period 2 test, gives up half of workforce

.Simply a handful of months after application the 1st person in a stage 2 test for freshly detected ...

Lilly, Haya ink $1B biobuck being overweight deal to search darker genome

.Eli Lilly's look for excessive weight intendeds has actually led it to the darker genome. The Big P...

ArsenalBio elevates $325M, turns off of past lead asset

.Arsenal Biosciences is moving on up. The cell therapy firm has added on $325 thousand in ammunition...

Lilly- supported fat loss biotech files IPO

.After increasing $170 million back in February, metabolic disease-focused BioAge Labs has actually ...

Aelis' cannabis use drug fails phase 2b, steering Indivior to reconsider $100M possibility

.Aelis Farma's chances of securing a quick, favorable decision on a $100 million option remittance h...

ProKidney halts phase 3 test certainly not needed to have for cell treatment approval

.ProKidney has actually stopped one of a pair of phase 3 trials for its tissue treatment for kidney ...

Vaxcyte climbs on 'impressive' 31-valent PCV succeed against Pfizer

.Vaxcyte revealed what analysts called "sensational" stage 1/2 records for its 31-valent pneumococca...

Recursion's human brain illness trial shows insufficient evidence of efficacy

.Recursion has actually stumbled via a very early test of its own tech-enabled strategy to drug expl...

Acepodia, Pfizer click on all together for chemistry-based tissue treatment

.Call it a case of good chemical make up: Acepodia, a biotech based upon Nobel Champion science, is ...